Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Financings

Telomir Pharmaceuticals, Inc.

Financings

RaiseDate
Private placement of common stock
Announced: about US$5.6M · US$1.16 a share · Alexander Capital, L.P.
Dealers: Alexander Capital, L.P. (lead)
Buyers: John Paul DeJoria (additional $1.0 million investment)
Use of proceeds: Clinical development of Telomir-Zn, including its Phase 1/2 program in advanced or metastatic TNBC, plus working capital and general corporate purposes
Oct 6, 2026
Capital contributions from former TELI shareholders
Closed: US$1M raised
Buyers: Certain former TELI shareholders ($1.0 million funded at closing; up to an additional $4.0 million in milestone-based contributions)
Apr 27, 2026
Milestone shares of common stock
Announced: up to US$5M
Buyers: certain TELI shareholders (up to $5 million in cash or cash equivalents: $1 million at closing, $2 million upon IND acceptance, $2 million upon Phase 1/2 initiation)
Use of proceeds: To advance development of Telomir-1
Oct 21, 2025
Strategic investment of restricted shares of common stock
Closed: US$3M raised · US$3 a share
Buyers: The Bayshore Trust (1 million restricted shares at $3.00 per share for $3 million)
Insiders: Purchased entirely by The Bayshore Trust, the Company's largest shareholder
Use of proceeds: Fund Telomir-1's upcoming IND submission for a rare disease indication and strengthen the balance sheet
May 21, 2025
Strategic investment of common stock
Closed: US$1M in the latest tranche · US$7 a share
Buyers: The Starwood Trust ($1 million in common stock at $7 per share)
Use of proceeds: To advance its scientific research and product development activities
Dec 17, 2024

Read by 6ix AI from the company's releases